• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Catheter Cardiovasc Interv. Impact of coronavirus disease 2019 (COVID-19) outbreak on outcome of myocardial infarction in Hong Kong, China

tetano

Editor, Senior Moderator
Catheter Cardiovasc Interv. 2020 May 5. doi: 10.1002/ccd.28943. [Epub ahead of print]
Impact of coronavirus disease 2019 (COVID-19) outbreak on outcome of myocardial infarction in Hong Kong, China.


Tam CF[SUP]1[/SUP], Cheung KS[SUP]2[/SUP], Lam S[SUP]1[/SUP], Wong A[SUP]1[/SUP], Yung A[SUP]1[/SUP], Sze M[SUP]1[/SUP], Fang J[SUP]1[/SUP], Tse HF[SUP]1[/SUP], Siu CW[SUP]1[/SUP].

Author information




Abstract

OBJECTIVE:

To determine whether COVID-19 may adversely affect outcome of myocardial infarction (MI) patients in Hong Kong, China.
BACKGROUND:

The COVID-19 pandemic has infected thousands of people and placed enormous stress on healthcare system. Apart from being an infectious disease, it may affect human behavior and healthcare resource allocation which potentially cause treatment delay in MI.
METHODS:

This was a single center cross-sectional observational study. From November 1, 2019 to March 31, 2020, we compared outcome of patients admitted for acute ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) before (group 1) and after (group 2) January 25, 2020 which was the date when Hong Kong hospitals launched emergency response measures to combat COVID-19.
RESULTS:

There was a reduction in daily emergency room attendance since January 25, 2020 (group 1,327/day vs. group 2,231/day) and 149 patients with diagnosis of MI were included into analysis (group 1 N = 85 vs. group 2 N = 64). For STEMI, patients in group 2 tended to have longer symptom-to-first medical contact time and more presented out of revascularization window (group 1 27.8 vs. group 2 33%). The primary composite outcome of in-hospital death, cardiogenic shock, sustained ventricular tachycardia or fibrillation (VT/VF) and use of mechanical circulatory support (MCS) was significantly worse in group 2 (14.1 vs. 29.7%, p = .02).
CONCLUSIONS:

More MI patients during COVID-19 outbreak had complicated in-hospital course and worse outcomes. Besides direct infectious complications, cardiology community has to acknowledge the indirect effect of communicable disease on our patients and system of care.
? 2020 Wiley Periodicals, Inc.



KEYWORDS:

ACS/NSTEMI; acute myocardial infarction/STEMI; health care outcomes


PMID:32367683DOI:10.1002/ccd.28943
 
Back
Top Bottom